Genprex

Monthly Archives: July 2018

Genprex Enters Agreement with the University of Texas MD Anderson Cancer Center to Study Oncoprex in Combination with Immunotherapies

AUSTIN, Texas & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jul. 26, 2018– Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, has entered a Sponsored Research Agreement (“Agreement”) with The University of Texas MD Anderson Cancer Center under which Genprexwill sponsor a pre-clinical study, entitled “A Novel Therapeutic Approach for the Treatment of Cancer Using a Combination of the Multifactorial Tumor Suppressor Gene TUSC2 and Immunotherapy,” to be conducted under the direction of Jack A….

Read More

Genprex To Present At The Singular Research Summer Solstice 2018 Conference

NEW YORK, July 18, 2018 /PRNewswire/ — Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced that Rodney Varner, Chairman and Chief Executive Officer, will present at the Singular Research Summer Solstice 2018 Conference to be held on July 19th in New York, New York….

Read More